Close Menu

NEW YORK (GenomeWeb) – Due to the availability of new data, Medicare contractor Noridian said it will retire a recently issued draft local coverage determination in which it proposed to limit coverage for a number of biomarker tests to guide decisions about adjuvant chemotherapy in breast cancer patients (see pdf below).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.